'Master switch' experimental drug could treat different cancers

July 11, 2012, Cancer Research UK
'Master switch' experimental drug could treat different cancers

(Medical Xpress) -- A unique multi-target experimental drug could treat a range of cancer types, according to research published in Clinical Cancer Research today.

Cancer Research UK-funded work at The Institute of Cancer Research in London shows that AT13148 – a type of drug called a kinase inhibitor – operates like a master switch to simultaneously block several different enzymes that control cancer cell growth and cell death.

Many kinase inhibitors have been developed that block only a single enzyme, but so far these drugs have shown only limited effectiveness. Scientists hope that switching off cell signals at multiple points could make the drug more likely to benefit patients and also delay drug resistance.

Laboratory tests showed that AT13148 was able to kill a range of cancer cell types including sarcoma, breast and prostate.

Lead author Dr. Michelle Garrett, team leader in the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, said: “Our study shows that this drug is effective against a range of tumour types, and operates by blocking multiple targets. These promising results have led to the decision to take the drug into patient trials.”

The molecule was originally discovered by scientists on the PKB discovery program, a collaboration between Astex Pharmaceuticals, Cancer Research Technology and The Institute of Cancer Research, which ran from 2003 through to 2006. The collaboration generated a series of compounds, of which a preferred candidate was then selected.

Dr. Julie Sharp, Cancer Research UK’s senior science information manager, said: “This is exciting research showing that this does the job of several drugs all at once, by targeting numerous weak spots in cancer cells.

“Using one to turn off the different faulty messages forcing cells to keep growing could be an effective way to destroy tumours. It could also reduce the chance of patients becoming resistant to treatment."

Explore further: CRT unveils 'screen test' for potential drugs to treat oestrogen positive breast cancer

More information: Yap et al. AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumour activity. Clinical Cancer Research (2012). DOI: 10.1158/1078-0432.CCR-11-3313

Related Stories

CRT unveils 'screen test' for potential drugs to treat oestrogen positive breast cancer

March 6, 2012
Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.

Gene silencing paves way to new treatments for breast cancer

October 21, 2011
(Medical Xpress) -- Cancer Research UK scientists have discovered that switching off a gene called CERT makes breast cancer cells more sensitive to a range of drugs. The research is published in the Journal of Pathology.

Class of breast cancer drugs could treat other types of cancer

November 9, 2011
(Medical Xpress) -- A class of drugs used to treat breast cancers which overproduce a protein called HER2 could also treat other types of cancer – particularly head and neck cancers, according to research presented at ...

Scientists find new drug target for hard-to-treat leukaemia

March 30, 2012
(Medical Xpress) -- Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia – a cancer with limited treatment options and relatively poor survival, according to research ...

Breakthrough could make 'smart drugs' effective for many cancer patients

June 27, 2011
(Medical Xpress) -- Newcastle and Harvard University reseachers have found that blocking a key component of the DNA repair process could extend the use of a new range of 'smart' cancer drugs called PARP inhibitors.

Drug combination domino effect destroys pancreatic cancer cells

February 22, 2012
(Medical Xpress) -- Cancer Research UK scientists have revealed how a combination of two very different drugs – currently being tested in clinical trials – amplifies the destruction of pancreatic cancer cells, according ...

Recommended for you

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

Workouts may boost life span after breast cancer

January 22, 2018
(HealthDay)—Longer survival after breast cancer may be as simple as staying fit, new research shows.

Cancer patients who tell their life story find more peace, less depression

January 22, 2018
Fifteen years ago, University of Wisconsin–Madison researcher Meg Wise began interviewing cancer patients nearing the end of life about how they were living with their diagnosis. She was surprised to find that many asked ...

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.